Until now, the Shingrix vaccine, recommended since March 2024 for people aged 18 and over whose immune system is failing, as well as for people aged 65 and over, was available in community pharmacies but without reimbursement.
It has been reimbursed since May at 100% only at the hospital as part of a so-called direct access system, an advance treatment procedure for certain medications.
Coverage by health insurance is planned for “prevention of shingles and postherpetic neuralgia in adults aged 65 and over, and adults aged 18 and over at increased risk of shingles”details the decree.
Shingrix already used in 40 countries
“This step also means that community pharmacists, nurses and medical biologists will now be able to prescribe and administer Shingrix”underlines in a press release the GSK laboratory which markets Shingrix in more than 40 countries.
Shingles, an infection that can affect anyone who has had chickenpox, is caused by reactivation of the varicella-zoster virus, which can occur when the immune system is weakened due to illness, treatment or age, according to the High Health Authority (HAS).
https://www.whatsupdoc-lemag.fr/article/la-has-simplifie-le-calendrier-vaccinal-pour-une-meilleure-observance-voici-les-changements
The HAS concluded in March that the effectiveness of the Shingrix vaccine was “much higher than that of the Zostavax vaccine” recommended since 2013 for the elderly.
With AFP
Health
